Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.60 |
| ▸ | MET | P08581 | 2/20 | 0.60 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.54 |
| ▸ | ROS1 | P08922 | 1/20 | 0.54 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.52 |
| ▸ | INSR | P06213 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24207001 | 0.86 | EGFR (0.59) | EGFRMETALKROS1PTK2 | |
| SCHEMBL21432297 | 0.84 | EGFR (0.77) | EGFRMETALKINSR | |
| SCHEMBL25306773 | 0.82 | EGFR (0.77) | EGFRMETALK | |
| SCHEMBL25370138 | 0.81 | EGFR (0.83) | EGFRMETALKINSR | |
| SCHEMBL25306866 | 0.81 | EGFR (0.69) | EGFRMETALKINSR | |
| SCHEMBL25300304 | 0.80 | EGFR (0.68) | EGFRMETALKINSR | |
| SCHEMBL25308104 | 0.80 | EGFR (0.85) | EGFRMETALKROS1PTK2 | |
| SCHEMBL25305317 | 0.80 | EGFR (0.71) | EGFRMETALKINSR | |
| SCHEMBL29059805 | 0.79 | EGFR (0.78) | EGFRMETALKROS1INSR | |
| SCHEMBL25299463 | 0.79 | ALK (0.72) | EGFRMETALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-24 | — | — | US | disclosed |
| WO-2022012622-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2022-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | EGFR, CBL, ERBB2 | EGFR 1/4885MET 63/4885ALK 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.